Skip to content
HowShorted

Altimmune, Inc. short interest in 2020

In 2020, Altimmune, Inc.'s disclosed short interest ran from 1.76% of shares outstanding on 15 Jan 2020 to 8.85% on 31 Dec 2020, a change of +7.09 percentage points. The year's high was 19.11% on 29 May 2020 and its low 1.57% on 14 Feb 2020, averaging 8.17% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.98 days on 15 Jan 2020. Full history: Altimmune, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Altimmune, Inc. in 2020

2020 in figures

Start of year
1.76% (15 Jan 2020)
End of year
8.85% (31 Dec 2020)
Change
+7.09 pp
High
19.11% (29 May 2020)
Low
1.57% (14 Feb 2020)
Average
8.17%
Highest days to cover
3.98 (15 Jan 2020)
SEC filings marked
9

Every report in 2020

Altimmune, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20201.76%3.98
31 Jan 20201.69%1.00
14 Feb 20201.57%1.71
28 Feb 20201.61%1.00
31 Mar 202012.94%1.5610-K filed, results (8-K)
15 Apr 202011.68%1.90
30 Apr 202010.62%3.27
15 May 202012.09%1.0010-Q filed, results (8-K)
29 May 202019.11%1.00
15 Jun 202017.19%1.41
30 Jun 202012.56%1.00
15 Jul 202014.18%1.00
14 Aug 20202.71%1.00results (8-K), 10-Q filed, results (8-K)
31 Aug 20203.11%1.00
15 Sep 20204.46%1.14
30 Sep 20206.33%1.28
15 Oct 20207.06%1.02
30 Oct 20208.85%3.43
13 Nov 20207.30%1.4310-Q filed, results (8-K)
30 Nov 20206.60%1.60
15 Dec 20207.52%1.09
31 Dec 20208.85%1.81

See also: Altimmune, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.